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Background: Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are widely
used in the management of congestive heart failure (CHF), diabetes mellitus (DM) and hypertension (HTN). Use of
these agents is reported to cause anemia.
Methods: We examined the association between standard care use of ACEI or ARB and subsequent change in
hemoglobin (Hgb) in a population of 701 adult primary care patients with DM, CHF and/or HTN. Data analysis was
conducted to adjust for baseline differences between the treatment groups.
Results: After adjusting for differences in covariates at baseline between the subjects who were prescribed ACEI
(N = 519) and ARB (N = 182), as well as the associated odds of being prescribed ARB, the ACEIs were associated
with lower mean Hgb [0.18 (0.02, 0.34) g/dL, p = 0.02] at follow up relative to ARBs. However, patients with CHF
experienced an increase in Hgb while on treatment (0.42 g/dL), especially those treated with ACEIs (0.56 g/dL).
Chronic kidney disease at baseline was not associated with a significant decrease in Hgb in either treatment group.
Conclusions: Since ACEIs and ARBs are most frequently used in patients who are vulnerable to complications from
anemia, such as patients with CHF, HTN and DM, these findings may be useful to clinicians in selecting medications
and monitoring patients for the adverse effects of treatment.
Keywords: Angiotensin converting enzyme inhibitors (ACEIs), Angiotensin receptor blockers (ARBs), Hemoglobin,
Anemia, Chronic kidney disease (CKD)Background
Angiotensin converting enzyme inhibitors (ACEIs) and
angiotensin receptor blockers (ARBs) are antihyperten-
sive drugs that are now in wide use for indications in
addition to the control of hypertension [1,2]. This wide
use is largely due to their renoprotective and cardiopro-
tective effects in patients with diabetes mellitus (DM)
and congestive heart failure (CHF).
In current practice ACEI/ARB medications are used for
multiple reasons, ranging from prevention of proteinuria
and progression to renal failure in diabetics, and first-line
treatment of hypertensive patients with concurrent CHF
and DM, to slowing the progression of heart failure and
improving survival in CHF patients. There is a complex* Correspondence: BJohnson3@eirh.org
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reproduction in any medium, provided the orrelationship between DM, CHF, and hypertension (HTN),
as worsening diabetic nephropathy and CHF can lead to
renal failure, causing HTN, further complicating the pri-
mary disease processes. ACEI/ARB medications have
several uses in this complex situation, but the main goal
is the prevention of complications, most notably renal
failure leading to end stage renal disease.
In the advanced stages of diseases like CHF and DM,
many patients develop some level of anemia. This is not
a benign finding. Anemia contributes to the worsening of
heart failure [3-5] and renal function [6,7] and in many
instances the treatment of anemia becomes part of the
management of the patient’s overall condition [8]. For
example, the “Anemia Correction in Diabetes” (ACORD)
trial demonstrated that correction of anemia prevented an
additional increase in left ventricular mass, and was asso-
ciated with a significant improvement in quality of life [8].td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of anemia in heart failure patients found anemia to be
associated with increased mortality in both systolic and
diastolic CHF and suggested that anemia could serve as
a useful prognostic marker [3]. Prevalence of anemia in
CHF is highly variable. Depending on the severity of
heart failure and diagnostic criteria for anemia, preva-
lence can be as high as 50% in selected patient cohorts
[3]. Lower Hgb levels are associated with greater func-
tional impairment and poor exercise tolerance. Patients
with incident anemia have the poorest survival, followed
by those with prevalent anemia and no anemia [4].
Analysis of Valsartan in Heart Failure Trial (Val-HeFT)
data also suggests that patients with larger decreases in
Hgb are at higher risk of hospitalization, morbidity and
mortality [9].
A prospective hospital based study concluded that
anemia is a significant predictor of decline in glomeru-
lar filtration rate (GFR) [6]. Decreased Hgb also serves
to identify type 2 diabetic patients who are at increased
risk of progression to advanced renal disease [6,10]. Over-
all, lower GFR is associated with lower Hgb level [11].
The current study was conducted to observe and com-
pare the effects of ACEIs and ARBs on Hgb levels in
adults with CHF, DM and/or HTN.
Methods
This was a retrospective case series based on the elec-
tronic health records (EHR) of adult patients served by
Essentia Health East in Duluth, MN. Eligible patients were
aged 40–70, had an Essentia Health East primary care
provider and received care within Essentia Health East
facilities between July 1, 2004 and September 30, 2009.
This study was reviewed and approved by the Essentia
Health Institutional Review Board.
Study population
To be included in the study, eligible patients were re-
quired to have (1) been initially prescribed ACEI or ARB
medications between January 1, 2005 and December 31,
2008, without a documented discontinuation for at least
6 months; (2) a diagnosis of DM, CHF, and/or HTN;
(3) documentation of baseline Hgb level (12 months
before to 10 days after initiation of ACEI or ARB medica-
tion) and Hgb level during the follow up period (3 to
12 months after initiation of medication); and (4) baseline
GFR or data needed to compute GFR (12 months before
to 30 days after initiation of medication). ACEI use has
been found to be associated with a decrease in erythro-
poietin concentrations after as little as 28 days; [12] in
this study follow up Hgb was assessed in the 3 to12
month window following the initiation of therapy. There
were 7042 eligible patients who were between 40 and
70 years of age at the time of treatment initiation.Patients were excluded from the study if their medical
record included evidence of (1) underlying conditions
associated with anemia (hemoglobinopathy, bleeding dis-
order, chronic inflammatory disease, or treatment with
vitamin B12 or folate) during the time from 6 months
before initiation of ACEI or ARB until the end of the
follow up period; or (2) other conditions or treatments
that might affect Hgb level during the follow up period
(blood transfusion, pregnancy, hemodialysis, malignancy
requiring chemotherapy or radiotherapy, hospitalization,
or treatment with EPO).
Following these exclusions, 5613 patients remained eli-
gible for the study. Of these, 5104 met inclusion criteria
(2), above, and 839 met both (2) and (3). The study
population consists of the 701 patients who met all four
inclusion criteria.
For eligible subjects data was extracted from the EHR:
age, sex, class of medication (ACEI or ARB), underlying
diagnoses (DM, CHF, and/or HTN), baseline Hgb and
GFR, and follow up Hgb. If more than one Hgb report
was recorded during the follow up period (3 to 12 months
after the initiation of medication), the measure closest
to 3 months was used. Chronic kidney disease (CKD)
was defined as GFR < 60 mL/min/1.73 m [2].
Data analysis
Preliminary analysis of the ACEI and ARB groups at
baseline identified differences between the treatment
groups with regard to sex; prevalence of HTN, CHF, and
CKD; and baseline Hgb; although not all differences
were significant at the 0.05 level. In addition, it was
noted that both the rate of prescription of ARB vs. ACEI
and the follow up Hgb decreased slightly over the four
year period. Accordingly, the fractional number of years
from January 1, 2005 until treatment was initiated was
included as a variable in the analysis. The investigators
recognized that in clinical practice, provider-selected
treatment is rarely, if ever, random. The preferential
ordering of ACEI or ARB for subpopulations defined by
sex and co-morbidities was not due to specific treatment
guidelines or standards of clinical practice. Accordingly,
the treatment effect of ARB relative to ACEI was consid-
ered to be truly confounded by the covariates for which
treatment group differences had been identified. It was
thus necessary to consider the associations between the
baseline covariates and both follow up Hgb and providers’
treatment choices, in order to produce an unbiased
estimate of the treatment effect.
We estimated the effect of the two treatments on follow
up Hgb with the use of the doubly robust (DR) semipara-
metric efficient estimator [13,14]. This method produces
an estimate of the causal effect of ARB vs. ACEI on follow
up Hgb by simultaneously incorporating (1) the chance
that a given subject would receive ACEI or ARB, given
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(2) the effects of baseline characteristics (covariates)
upon the outcome of interest (follow up Hgb). This
approach to data analysis is “doubly robust” in the sense
that the model produces an unbiased estimate of the
causal effect if either (1) the effect of baseline covari-
ates on the outcome or (2) the propensity score is cor-
rect. A complete-case ANCOVA was conducted. All
analyses were completed using SAS ver. 9.2 and the
SAS macro, %drmacro, described by Funk et al. [15]
was used to produce the estimated causal effect and
asymptotic confidence interval (CI). The bias-corrected
and accelerated (BCa) bootstrap CI [16] of the causal
effect was constructed for comparison with the asymp-
totic CI.
Results
In all, EHR data for 701 patients met study inclusion
and exclusion criteria, with 519 patients receiving ACEI
treatment and 182 receiving ARB. On average, the two
Hgb tests were 314 days apart and the second one was
227 days after the initiation of treatment. The mean age
for all treated patients was 57.53 +/− 7.73, with more men
(54.4%) than women in the study population. Table 1 pro-
vides a summary of the baseline demographic and clinical
characteristics of the two treatment groups, with associ-
ated p-values.
The estimated effects of baseline demographic and clin-
ical characteristics on follow up hemoglobin are summa-
rized in Table 2, both for the entire population studied
(N = 701), and for the ACEI (N = 519) and ARB (N= 182)
populations separately. Table 2 also summarizes the
odds (odds ratio) that subjects with these characteristics
received ARB (relative to ACEIs) treatment. The doubly
robust analysis was based on these data.
Sex, CHF, and baseline Hgb were associated with
statistically significant effects on follow up Hgb. PatientsTable 1 Demographics by study group
Variable Overall A
(N = 701)
Age 57.53 +/− 7.73 57
Sex (female) 320 (45.6)
Hgb 14.58 +/− 1.43 14
GFR 76.61 +/− 19.66 76.
CKD 118 (16.8)
Diabetes mellitus 263 (37.5)
Hypertension 657 (93.7)
CHF 47 (6.7)
Days between Hgb tests 313.68 +/− 120.77 312.
FUP days 226.70 +/− 81.39 226with CHF were noted to have an increase in Hgb while
on treatment (0.42 g/dl); this was especially noted in
those treated with ACEIs (0.56 g/dl). While we observed
that baseline CKD was associated with a decrease in Hgb
(overall −0.15 g/dl, ACEI group −0.09 g/dl, ARB −0.31 g/dl),
the difference between the two treatment groups was not
statistically significant. In addition, ACEIs and ARBs were
prescribed at different rates for different subpopulations,
with ARBs prescribed more often for females and for
subjects with an earlier treatment initiation date, as well
as those with HTN, CHF, and with a lower baseline
Hgb. Accordingly, (1) the likelihood that a subject with
a specific set of baseline characteristics would receive
ARBs (the propensity score), and (2) the observed follow
up Hgb associated with each set of baseline characteris-
tics were used in the doubly robust estimate of the effect
of treatment on follow up Hgb.
The unadjusted mean Hgb for patients who had re-
ceived ACEIs was 0.30 (0.21, 0.39) g/dL lower at follow
up than at baseline (14.37 vs. 14.67 g/dL), while the un-
adjusted mean Hgb for patients who had received ARBs
was essentially unchanged from baseline at 14.32 g/dL.
Thus the raw (unadjusted) difference between the ACEI
and ARB effects on Hgb was significant (p = 0.0008). After
accounting for the effect of baseline covariates and adjust-
ing for differential prescription of ACEI or ARB (propen-
sity), the estimated follow up Hgb and 95% confidence
intervals for ACEI and ARB treatment were 14.32 (14.21,
14.42) g/dL and 14.50 (14.35, 14.65) g/dL, respectively
(see Table 3). The ACEIs were associated with lower mean
Hgb [0.18 (0.02, 0.34) g/dL, p = 0.02] at follow up relative
to ARBs. These results are consistent with those obtained
by bootstrap, with 100,000 replications, which found an
estimated causal effect of 0.18 (0.01, 0.33) g/dL. Chronic
kidney disease at baseline was not associated with a
greater decrease in Hgb in the study population as a
whole, or in either treatment group.CEI group ARB group p-value
(N = 519) (N = 182)
.45 +/− 7.74 57.75 +/− 7.72 0.6484
221 (42.6) 99 (54.4) 0.0073
.67 +/− 1.39 14.32 +/− 1.51 0.0063
87 +/− 18.65 75.87 +/− 22.35 0.5898
80 (15.4) 38 (20.9) 0.1066
191 (36.8) 72 (39.6) 0.5339
481 (92.7) 176 (96.7) 0.0738
29 (5.6) 18 (9.9) 0.0572
34 +/− 118.40 317.50 +/− 127.56 0.6332
.02 +/− 82.34 228.64 +/− 78.83 0.7026
Table 2 Impact of baseline covariates on (1) odds of receiving ARB relative to ACEI and (2) follow up Hgb levels
(Factors Used in Doubly Robust Analysis)
Effect on follow up Hgb in g/dL (95% CI)
Overall ACEI ARB
Baseline covariate OR (95% CI) for receiving ARB relative to ACEI (N = 701) (N = 519) (N = 182)
AGE 1.00 (0.98, 1.02) 0.00 (−0.01, 0.01) −0.00 (−0.01, 0.01) −0.00 (−0.02, 0.02)
Sex (female) 1.40 (0.96, 2.05) −0.32 (−0.47, -0.17) −0.29 (−0.47, -0.11) −0.47 (−0.75, -0.20)
Diabetes mellitus 1.16 (0.81, 1.67) 0.01 (−0.14, 0.15) −0.03 (−0.20, 0.15) 0.15 (−0.13, 0.42)
Hypertension 2.82 (1.12, 7.13) 0.29 (−0.01, 0.58) 0.21 (−0.12, 0.54) 0.49 (−0.24, 1.22)
CHF 1.90 (0.98, 3.68) 0.42 (0.14, 0.70) 0.56 (0.20, 0.91) 0.13 (−0.33, 0.58)
Hgb (pre) 0.89 (0.78, 1.02) 0.59 ( 0.53, 0.64) 0.60 (0.54, 0.66) 0.57 (0.48, 0.66)
CKD 1.19 (0.75, 1.89) −0.15 (−0.34, 0.04) −0.09 (−0.31, 0.14) −0.31 (−0.64, 0.03)
Year of initiation of treatment 0.86 (0.74, 1.01) −0.05 (−0.11, 0.01) −0.05 (−0.13, 0.02) −0.03 (−0.15, 0.09)
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We found that the use of ACEIs was associated with a
decrease in Hgb levels, while the use of ARBs was not.
After adjustment for the differences between the ACEI
and ARB populations at baseline, the difference in follow
up Hgb between the ACEI and ARB groups was found
to be statistically significant. Since these drugs are most
frequently used in patients who are vulnerable to compli-
cations from anemia, such as older patients with cardiac
conditions, these findings may be useful to clinicians in
selecting medications and monitoring patients for the
adverse effects of treatment.
The mechanism of action of ACEIs and ARBs and
their effects on hemoglobin level are not well estab-
lished. Several studies have concluded that ACEIs may
interfere with the production of erythropoietin (EPO)
[12,17]. A study of kidney transplant patients concluded
that ACEI related reduction in hemoglobin could re-
flect the modulation of multiple factors interacting with
erythroid marrow progenitors [17]. An association be-
tween ACEI therapy, decrease in Hgb and suppression
of EPO production has also been documented [18].
Angiotensin 2 increases proliferation of early erythroid
progenitors but not the progenitors of other cell lines
and ARB completely abolishes this effect [19]. These ob-
servations point to a possible inhibitory effect of these
medications on bone marrow.Table 3 Follow up hemoglobin after ACEI or ARB treatment,
adjusted for baseline covariates
Treatment Estimated follow up
Hgb (g/dL)
Confidence interval p-value
ACEI 14.32 (14.21, 14.42)
ARB 14.50 (14.35, 14.65)
Difference 0.18 (0.02, 0.34) 0.02This study presented a challenge that is common in
observational research: adjusting for baseline differences
in treatment groups. That is, in determining the effect
of ACEI and ARB medications on Hgb levels, we first
had to adjust for the impact of other known factors. For
example, both baseline Hgb and patient sex had larger
effects on follow up Hgb than either of the classes of
medications studied. Similarly, while the lower mean
Hgb value at baseline in the ARB group (14.32 +/− 1.51)
when compared to the ACEI group (14.67 +/− 1.39)
might have been partially explained by the greater pro-
portion of females in that group (54.4% vs. 42.6%), the
magnitude of this effect was unknown. We also ob-
served in this study that patients with CHF experienced
an increase in Hgb while on treatment. This may be re-
lated to improvement in hemodilution in these patients
as their CHF improves with ACEI therapy, as hemodilu-
tion is one of the possible etiologies of anemia in chronic
CHF patients [20,21]. The reasons for the observed differ-
ences in the other covariates at baseline were also unclear,
but ultimately could be rendered moot if the data analysis
could fully adjust for the differences. The adjustment for
baseline differences in covariates was the principal consid-
eration in the selection of the analysis methods used in
this study.
In planning this study, we were interested in determin-
ing if baseline level of renal function would affect the
magnitude of the drop in Hgb with either of the classes
of drugs studied. Worsening chronic kidney disease (CKD)
is frequently associated with declining Hgb levels, and
several studies have found that ACEI or ARB drugs may
contribute to or exacerbate anemia [4,7,18,22]. In the
current study, the presence of baseline CKD was found
to be associated with a decline in Hgb in both ACEI
(−0.09 g/dL) and ARB (−0.31 g/dL) patients, but the
effect of CKD was not statistically significant. In 2008,
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of Japanese patients using ACEI/ARB and found that
the use of ARB was associated with a decrease in Hgb in
patients with diabetic nephropathy. Of note is the study
selection of patients with GFR < 60 mL/min/1.73 m [2].
As well-documented in the literature and National
Kidney Foundation guidelines, advanced renal disease
is associated with anemia independent of other risk fac-
tors. Therefore, we determined that it would be reasonable
to study the effects of ACEI and ARB in heart failure
and diabetic patients with early disease who have rela-
tively well preserved kidney function.
Our finding that the use of ACEIs, compared with
ARBs, was associated with a lower follow up Hgb after
adjusting for covariates appears to be at variance with
the findings of Inoue et al. [7] who reported a significant
decrease in Hgb with ARBs (−0.54 ± 1.02 g/dL, p < 0.001),
but not with ACEIs in their study of Type II diabetic
patients with chronic kidney disease [7].
Conclusions
We found that the use ACEIs was associated with a
lower Hgb at follow up, while the use of ARBs was not.
The difference was small but statistically significant. Clini-
cians should consider possible effects of ACEI and ARB
therapy on Hgb, especially in ambulatory patients with
unexplained anemia. An improved understanding of the
association between the use of ACEI and ARB therapy
and the development of anemia could contribute signifi-
cantly to the management of patients with DM, CHF
and HTN.
Study limitations
This study was subject to several limitations. The sample
(N = 701) was not large enough for extensive analysis of
the effects of ACEI/ARB therapy in subgroups. In addition,
while the study was designed to examine the impact of
incident (new) use of ACEI and ARB medications, the
study population may have included some individuals
who were already receiving ACEI or ARB medications
at baseline. The study population was limited to patients
who already had primary care physicians at Essentia
Health East prior to the initiation of ACEI/ARB therapy,
so that the EHR could be used to exclude patients
with known prior use of ACEIs/ARBs. This study was
conducted in the Essentia Health East service area of
Northwestern Wisconsin and Northeastern Minnesota,
and the subjects doubtlessly reflected the limited ethnic
diversity of the region.
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